Please assess the completion status of the following clinical trial:

Trial Title: Vascular Effects of Carvedilol Versus Metoprolol in Hypertensive Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 30-80 years old~* Documented history of type 2 diabetes~* Stable angiotensin converting enzyme/angiotensin receptor blocker (ACE/ARB) regimen 30 days before and throughout the study period~* Stable anti-diabetic regimen throughout the study period~* Body mass index (BMI) between 22-45 kg/m2~* HbA1c between 6-9% for patients on anti-diabetic treatment regimen and HbA1c between 6-8% for patients who are being controlled by diet alone~* Screening blood pressure (BP) \> 130/80 (average of 3 sitting measurements), with current medications~Exclusion Criteria:~* Uncontrollable or symptomatic arrhythmias~* Unstable angina~* Sick sinus syndrome or second or third degree heart block~* Decompensated heart failure~* Myocardial infarction (MI) or stroke within 3 months of screening~* Bradycardia~* Chronic obstructive pulmonary disease (COPD) with required inhaled or oral bronchodilators or corticosteroids~* Bronchial asthma or related bronchospastic conditions~* New onset/diagnosed type 2 diabetes (\<3 months)~* Clinically significant renal or liver disease (creatinine \>2.5 mg/dL)~* Endocrine disorders~* Use of anorectic or other diet drugs inconsistent with recommendations for type 2 diabetics~* Use of beta-blockers within 3 months of screening~* Use of corticosteroids~* Systemic disease, including cancer, with reduced life expectancy (\<12 months)~* Psychological illness/condition that interferes with comprehension of study requirements~* Use of an investigational drug within 30 days of entry into study

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Carvedilol (Type: EXPERIMENTAL): Carvedilol, orally, 25 mg, twice daily for five months
- Metoprolol (Type: ACTIVE_COMPARATOR): Metoprolol, orally, 200 mg, twice daily for five months.

Based on this trial design, predict the completion outcome and termination type (if applicable).